John M. Strother

493 total citations
6 papers, 420 citations indexed

About

John M. Strother is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, John M. Strother has authored 6 papers receiving a total of 420 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Cancer Research and 3 papers in Molecular Biology. Recurrent topics in John M. Strother's work include Cancer Genomics and Diagnostics (3 papers), Renal cell carcinoma treatment (2 papers) and Blood properties and coagulation (1 paper). John M. Strother is often cited by papers focused on Cancer Genomics and Diagnostics (3 papers), Renal cell carcinoma treatment (2 papers) and Blood properties and coagulation (1 paper). John M. Strother collaborates with scholars based in United States and Germany. John M. Strother's co-authors include Alistair J. Barber, Bei Xu, Diana Tănase, Erich Lieth, MAGDALENA RATZ, Tomasz M. Beer, Robert Dreicer, Brendan D. Curti, Erik D. Roberson and Deirdre Nauman and has published in prestigious journals such as Journal of Clinical Oncology, Diabetes and European Journal of Cancer.

In The Last Decade

John M. Strother

6 papers receiving 409 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John M. Strother United States	4	247	239	92	83	81	6	420
Xiaoxia Zeng China	5	185 0.7×	234 1.0×	79 0.9×	113 1.4×	62 0.8×	11	379
Chika Harada Japan	10	364 1.5×	271 1.1×	50 0.5×	106 1.3×	124 1.5×	18	594
Takahiko Noro Japan	15	332 1.3×	385 1.6×	115 1.3×	114 1.4×	101 1.2×	34	642
Masayuki Fukuhara Japan	10	218 0.9×	143 0.6×	62 0.7×	104 1.3×	46 0.6×	13	424
Rupali Vohra Denmark	14	317 1.3×	391 1.6×	111 1.2×	146 1.8×	75 0.9×	28	611
Karen Duong‐Polk United States	12	384 1.6×	295 1.2×	63 0.7×	76 0.9×	74 0.9×	16	603
Taeko Horie Japan	12	201 0.8×	198 0.8×	90 1.0×	89 1.1×	56 0.7×	29	426
J.–W. Chung South Korea	6	259 1.0×	244 1.0×	109 1.2×	61 0.7×	84 1.0×	7	427
Yun‐Zheng Le United States	10	408 1.7×	339 1.4×	129 1.4×	55 0.7×	56 0.7×	11	575
Remya Robinson India	10	294 1.2×	187 0.8×	102 1.1×	44 0.5×	82 1.0×	11	539

Countries citing papers authored by John M. Strother

Since Specialization

Citations

This map shows the geographic impact of John M. Strother's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Strother with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Strother more than expected).

Fields of papers citing papers by John M. Strother

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John M. Strother. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Strother. The network helps show where John M. Strother may publish in the future.

Co-authorship network of co-authors of John M. Strother

This figure shows the co-authorship network connecting the top 25 collaborators of John M. Strother. A scholar is included among the top collaborators of John M. Strother based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John M. Strother. John M. Strother is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Feng, Zizhen, Brendan D. Curti, David I. Quinn, et al.. (2022). A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer. 20(5). 415–422. 2 indexed citations

2.

Chen, Emerson Y., Gina M. Vaccaro, John M. Strother, et al.. (2018). A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer. Anticancer Research. 39(1). 245–252. 3 indexed citations

3.

Anderson, Brian, Joshua M. Johnston, Andrew S. Terker, et al.. (2010). Severe bleeding in a woman heterozygous for the fibrinogen γR275C mutation. Blood Coagulation & Fibrinolysis. 21(5). 494–497. 3 indexed citations

4.

Ryan, Chris, Brendan D. Curti, David I. Quinn, et al.. (2010). A phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC).. Journal of Clinical Oncology. 28(15_suppl). 4528–4528. 5 indexed citations

5.

Strother, John M., Tomasz M. Beer, & Robert Dreicer. (2005). Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?. European Journal of Cancer. 41(6). 954–964. 11 indexed citations

6.

Lieth, Erich, Alistair J. Barber, Bei Xu, et al.. (1998). Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group.. Diabetes. 47(5). 815–820. 396 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact